A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure.
Phase of Trial: Phase IV
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GAUDI
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.